Aimmune Therapeutics (NASDAQ:AIMT) Cut to Hold at ValuEngine

ValuEngine lowered shares of Aimmune Therapeutics (NASDAQ:AIMT) from a buy rating to a hold rating in a report released on Thursday, ValuEngine reports.

Several other research analysts also recently commented on AIMT. Credit Suisse Group cut their price objective on shares of Athene from $67.00 to $57.00 and set an outperform rating for the company in a report on Tuesday, May 21st. Wedbush reissued a buy rating and issued a $36.00 price target on shares of Allena Pharmaceuticals in a report on Tuesday, July 2nd. BidaskClub raised shares of Zillow Group from a buy rating to a strong-buy rating in a report on Tuesday, July 2nd. Cantor Fitzgerald reissued a buy rating and issued a $27.00 price target on shares of Spero Therapeutics in a report on Thursday, May 9th. Finally, Zacks Investment Research raised shares of DLH from a sell rating to a hold rating in a report on Tuesday, July 9th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $41.43.

AIMT opened at $19.00 on Thursday. The business has a 50 day simple moving average of $20.17. Aimmune Therapeutics has a 12 month low of $16.95 and a 12 month high of $36.12. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.19.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.87) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.07. On average, equities analysts expect that Aimmune Therapeutics will post -3.77 earnings per share for the current year.

Large investors have recently made changes to their positions in the business. Cable Hill Partners LLC raised its position in Aimmune Therapeutics by 81.7% in the 1st quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 500 shares during the period. Manchester Capital Management LLC purchased a new position in Aimmune Therapeutics in the 1st quarter worth $27,000. Pearl River Capital LLC purchased a new position in Aimmune Therapeutics in the 1st quarter worth $28,000. Marshall Wace North America L.P. purchased a new position in Aimmune Therapeutics in the 1st quarter worth $32,000. Finally, Advisor Group Inc. raised its position in Aimmune Therapeutics by 84.6% in the 4th quarter. Advisor Group Inc. now owns 1,737 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 796 shares during the period. 76.12% of the stock is owned by hedge funds and other institutional investors.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

See Also: Holder of Record

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.